Document is current
Any future updates will be listed below
-
Authors
Ecker, Christine
Pretzsch, Charlotte M. https://orcid.org/0000-0002-2761-6628
Leyhausen, Johanna https://orcid.org/0000-0003-1438-4001
Berg, Lisa M.
Gurr, Caroline
Seelemeyer, Hanna
McAlonan, Grainne https://orcid.org/0000-0002-4466-2343
Puts, Nicolaas A. https://orcid.org/0000-0003-1024-1927
Loth, Eva https://orcid.org/0000-0001-9458-9167
Dell’Aqua, Flavio https://orcid.org/0000-0001-5313-5476
Mason, Luke
Charman, Tony https://orcid.org/0000-0003-1993-6549
Oakley, Bethany
Bourgeron, Thomas
Beckmann, Christian
Buitelaar, Jan K. https://orcid.org/0000-0001-8288-7757
Arango, Celso https://orcid.org/0000-0003-3382-4754
Banaschewski, Tobias https://orcid.org/0000-0003-4595-1144
Chiocchetti, Andreas G.
Freitag, Christine M. https://orcid.org/0000-0001-9676-4782
Hattingen, Elke
Krueger-Burg, Dilja https://orcid.org/0000-0001-5597-6287
Schmeisser, Michael J.
Repple, Jonathan
Reif, Andreas
Murphy, Declan G. https://orcid.org/0000-0002-6664-7451
- License Information
-
More Information
Article History
Received: 14 February 2024
Accepted: 4 July 2025
First Online: 22 July 2025
Competing interests
: J.K.B. has been in the past three years a consultant to/member of advisory board of/and/or speaker for Janssen Cilag BV, Takeda/Shire, Roche, Novartis, Medice, Angelini, and Servier. He is not an employee of any of these companies and not a stock shareholder of any of these companies. He has no other financial or material support, including expert testimony, patents, and royalties. TBa served in an advisory or consultancy role for AGB pharma, eye level, Infectopharm, Medice, Neurim Pharmaceuticals, Oberberg GmbH and Takeda. He received conference support or speaker’s fee by AGB pharma, Janssen-Cilag, Medice and Takeda. He received royalties from Hogrefe, Kohlhammer, CIP Medien, Oxford University Press; the present work is unrelated to these relationships. T.C. has received royalties from Sage Publications and Guilford Publications. J.R. has received speaker’s honoraria from Janssen, Hexal, Neuraxpharm and Novartis. D.G.M. has received consultancy fees from Roche and Servier. A.R. has received honoraria for lectures and/or advisory boards from Janssen, Boehringer Ingelheim, Compass, GH Research, SAGE/Biogen, LivaNova, Medice, Shire/Takeda, Newron, MSD, AbbVie, cyclerion. Also, he has received research grants from Medice and Janssen. The remaining authors declare no competing interests.
